butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine has been researched along with Hemorrhagic Shock in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, J; Guo, S; Ji, YD; Li, B; Li, HB; Liu, M; Shang, Y; Tang, M; Wang, GZ; Wu, ZY; Yao, SL; Yuan, SY | 1 |
| Gong, J; Guo, S; Li, HB; Shang, Y; Yao, SL; Yuan, SY | 1 |
1 trial(s) available for butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine and Hemorrhagic Shock
| Article | Year |
|---|---|
BML-111, a lipoxin receptor agonist, protects haemorrhagic shock-induced acute lung injury in rats.
Topics: Acute Lung Injury; Animals; Blotting, Western; Cell Adhesion Molecules; Electrophoretic Mobility Shift Assay; Heptanoic Acids; Lung; Male; NF-kappa B; Oligopeptides; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Lipoxin; Resuscitation; Shock, Hemorrhagic | 2012 |
1 other study(ies) available for butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine and Hemorrhagic Shock
| Article | Year |
|---|---|
BML-111 attenuates hemorrhagic shock-induced acute lung injury through inhibiting activation of mitogen-activated protein kinase pathway in rats.
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Heptanoic Acids; Interleukin-1beta; Interleukin-6; Lung; Male; Mitogen-Activated Protein Kinase Kinases; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptors, Lipoxin; Shock, Hemorrhagic; Signal Transduction; Transcription Factor AP-1 | 2013 |